06.30.2008 -  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings

06.19.2008 -  Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections

05.20.2008 -  Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results

05.20.2008 -  Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD

05.15.2008 -  Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress

05.12.2008 -  Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement

05.07.2008 -  Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents

04.15.2008 -  Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment

04.07.2008 -  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings

03.19.2008 -  Forest Laboratories Announces Resignation of Ivan Gergel, MD

03.04.2008 -  Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies

02.27.2008 -  Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (Nebivolol) Agreement

02.21.2008 -  Forest and Cypress Announce FDA Acceptance for Review of New Drug Application for Milnacipran for the Treatment of Fibromyalgia

02.05.2008 -  Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation

01.25.2008 -  Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement

01.22.2008 -  Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor

01.15.2008 -  Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share of $0.96. Raises FY2008 EPS Guidance Range to $3.35-$3.45 Excluding $0.15 per Share Licensing Charge

01.10.2008 -  Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Lawsuits Against Several Companies for Patent Infringement

01.04.2008 -  Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Third Quarter Earnings